Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02452489
Other study ID # ChangchunUCM02
Secondary ID
Status Recruiting
Phase Phase 1
First received May 20, 2015
Last updated May 21, 2015
Start date January 2015
Est. completion date August 2018

Study information

Verified date May 2015
Source Changchun University of Chinese Medicine
Contact Tie Li, Ph.D
Phone +86 0431 86714973
Email zusanli_1999@126.com
Is FDA regulated No
Health authority National Health and Family Planning Commision of the People's Republic of China,People's Republic of China:
Study type Interventional

Clinical Trial Summary

With Diabetic gastroparesis as the research object, by the method of multi-center RCT and single cavity and different acupuncture acupoints compatibility treatment of diabetic gastroparesis, the inspection of gastric emptying, gastric dynamic inspection, such as validity checking means, for single cavity with different acupoints compatibility evaluate clinical efficacy of treatment of diabetic gastroparesis.


Description:

In order to establish a spectrum of acupoints compatibility of the law, is clear about the factors affecting the compatibility effect of acupoints, the formation of strong operability of acupoints compatibility optimization evaluation method, the project choice of the clinical acupuncture and moxibustion have curative effect of diabetic gastroparesis as the breakthrough point of the study, carried out clinical multi-center RCT research, through objective and scientific evaluation method, comparing the effect of different acupoints compatibility.

Diabetic gastroparesis in clinical common disease, frequently-occurring disease, acupuncture curative effect is distinct, disease diagnosis, curative effect evaluation standard. Previous clinical data also show that the diabetic gastroparesis is acupuncture clinical diseases. This project by diabetic gastroparesis as the research object, research to better guide clinical practice, improve the clinical curative effect, promote acupuncture of the inheritance and innovation, promote scientification of acupuncture and moxibustion, modernization and internationalization, and will have broad prospect of application and significant scientific research value.


Recruitment information / eligibility

Status Recruiting
Enrollment 99
Est. completion date August 2018
Est. primary completion date December 2017
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Clinical diagnosis of Diabetic Gastroparesis;

- Aged 18-60 (including 18 and 60);

- Fasting venous blood sugar =7.8mmol/L,2-hour post-meal blood glucose = 13.6mmol/ L;

- Diabetes more than 3 years;

- Diet and exercise therapy or diet movement and exercise therapy based on the use of hypoglycemic drugs (except alpha glycosidase inhibitor) treatment, dose stable at least more than 3 months;

- Rounding out the top three months did not participate in any clinical subjects;

- Sign the informed consent and voluntary to participate in the study.

Exclusion Criteria:

- Patients with reflux esophagitis;

- Postoperative gastroparesis patients;

- Ketoacidosis, non ketosis acute complications such as hypertonic coma;

- Patients with acute cardiovascular disease, with severe trauma or surgery, severe infections, pregnancy or breast-feeding women;

- Patients with myocardial infa,acute coronary syndrome (ACS),coronary revascularization;

- Patients with severe liver disease, or the AST and/or ALT 2 times higher than normal ceiling;

- Patients with Serum creatinine kidney damage, more than 140 umol/L;

- Patients with obvious blood system diseases (either in person are not to be included in the item: Hb: men < 110 g/L, women < 100 g/L, the WBC < 3.5×109/L/L, PLT < 80×109/L);

- Patients's systolic pressure=180mmHg,Patients's diastolic pressure=100mmHg;

- Patients with Advanced malignant tumor or other serious wasting disease, infection and bleeding;

- Endoscopy has the organic lesion such as peptic ulcer;

- Disorders or do not fit the person and the growing experiment condition or severe complications;

- Nearly four weeks of alpha glycosidase inhibitor drugs.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Device:
acupuncture
Patients will be acupuncture with Zhongwan(RN12),needle 1 times a day,30 min/time,5 days for a period of treatment,the treatment interval for two days,three intervention treatment,follow-up after 4 weeks.
acupuncture
Patients in Combination of He-Mu points group,will be acupuncture with Zusanli(ST36) and Zhongwan(RN12),needle 1 times a day,30 min/time,5 days for a period of treatment,the treatment interval for two days,three intervention treatment, follow-up after 4 weeks.
acupuncture
Patients in Control group,will be acupuncture with at the junction of deltoid and biceps,needle 1 times a day,30 min/time,5 days for a period of treatment,the treatment interval for two days,three intervention treatment,follow-up after 4 weeks.

Locations

Country Name City State
China The Affiliated Hospital To Changchun University of Chinese Medicine Changchun Jilin

Sponsors (6)

Lead Sponsor Collaborator
Changchun University of Chinese Medicine Hengyang Traditional Chinese Medicine Hospital, Jilin University, Qilu Hospital, Second People's Hospital of Hunan, The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Gastroparesis Symptoms Rating Scale(GCSI) 8 weeks No
Secondary FBG(fasting blood-glucose) 8 weeks No
Secondary PPG(postprandial blood sugar) 8 weeks No
Secondary Gastric emptying check by Color ultrasonography 8 weeks No
Secondary Gastric emptying check by X rays 8 weeks No
Secondary Short form 36 health survey(SF-36) 8 weeks No
Secondary Self-rating anxiety scale(SAS) 1 week No
Secondary Self-Rating Depression Scale(SDS) 1 week No
See also
  Status Clinical Trial Phase
Completed NCT01557296 - Evaluation of Diagnostic Methods and Dietary Treatment of Diabetic Gastroparesis Phase 2
Withdrawn NCT03376399 - Potential Benefits of Sleeve Gastrectomy Surgery on Diabetic Gastroparesis Symptoms
Not yet recruiting NCT02264587 - Effects and Mechanism of Mosapride Citrate on Diabetic Gastroparesis Phase 4
Completed NCT02289846 - Trial of IW-9179 in Patients With Diabetic Gastroparesis (DGP) Phase 2
Completed NCT03544229 - A Study to Evaluate the Efficacy and Safety of TAK-906 in Adult Participants With Symptomatic Idiopathic or Diabetic Gastroparesis Phase 2
Recruiting NCT04706832 - Thoracic Splanchnic Magnetic Neuromodulation Therapy (ThorS-MagNT) for Grade 3 Diabetic Gastroparesis: Pilot Study N/A
Not yet recruiting NCT05584462 - Gastroparesis in type2 Diabetic Patient
Enrolling by invitation NCT05812339 - Body Surface Gastric Mapping to Evaluate Patients With Upper Gastrointestinal Symptoms and Controls
Completed NCT02732821 - G-POEM for Treatment of Refractory Gastroparesis
Completed NCT01030341 - Continuous Glucose Monitoring and Insulin Pump Therapy in Diabetic Gastroparesis N/A
Recruiting NCT05832151 - A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis Phase 2
Completed NCT02025725 - Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Women With Diabetic Gastroparesis Phase 3
Completed NCT01916460 - Intraluminal Endosonography for Examination of the Structural Changes of the Stomach in Gastroparetic Patients N/A
Completed NCT01469286 - Transcutaneous Electroacupuncture for Gastroparesis Phase 1
Terminated NCT00874133 - The Effect of Acupuncture on Symptoms, Gastric Emptying Rate and Glucose Control in Patients With Diabetic Gastroparesis N/A
Completed NCT01126034 - Improving Metoclopramide Prescribing Practices at Penn Through a Physician-targeted Intervention N/A
Recruiting NCT05273788 - Thoracic Neuromodulation for Diabetic Gastroparesis N/A
Suspended NCT00470795 - Acupuncture for Diabetic Gastroparesis Phase 3
Completed NCT00139893 - A Randomized, Open-label, Two-way Crossover Trial to Determine the Pharmacokinetics of Metoclopramide When Administered as the Orally Disintegrating Tablet Compared to Reglan® Tablets in Subjects With Diabetic Gastroparesis N/A
Recruiting NCT04254549 - Rifaximin in Patients With Diabetic Gastroparesis Phase 2